Valuation: C4 Therapeutics, Inc.

Market Cap 517M 443M 416M 380M 717M 49.28B 721M 4.93B 1.91B 24.86B 1.94B 1.9B 82.35B P/E 2026 *
-4.81x
P/E 2027 * -4.33x
Enterprise Value 517M 443M 416M 380M 717M 49.28B 721M 4.93B 1.91B 24.86B 1.94B 1.9B 82.35B EV / Sales 2026 *
24.1x
EV / Sales 2027 * 25.2x
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+0.12%
1 week-0.24%
Current month+20.69%
1 month+16.99%
3 months+20.34%
6 months+51.08%
Current year+119.90%
1 week 3.81
Extreme 3.81
4.24
1 month 3.36
Extreme 3.36
4.38
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Fiscal year

Chief Technology Officer

22,722 0.0206%
01/07/26 Free

Director

3,341 0.0030%
01/07/26 Free

Founder

2,650 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%-0.24%+63.42%+33.33% 517M
-1.01%+1.48%+1.66%+23.62% 51.65B
+0.39%-1.11%+469.50%+558.03% 45.31B
+0.88%+4.80%+39.14%+17.79% 42.7B
-0.28%-0.49%+21.40%+85.58% 42.79B
-2.27%-3.02%+14.22%+51.50% 32.87B
+0.49%+1.59%+31.68%+136.18% 17.14B
-1.09%-3.68% - - 16.61B
-1.70%+4.54%+9.11%+30.36% 15.01B
-0.46%+2.27%+81.16%+49.22% 14.21B
Average -0.50%+2.72%+81.25%+109.51% 27.88B
Weighted average by Cap. -0.46%+2.74%+100.22%+137.77%

Financials

2026 *2027 *
Net sales 21.42M 18.39M 17.26M 15.76M 29.75M 2.04B 29.89M 204M 79.16M 1.03B 80.44M 78.7M 3.41B 20.54M 17.63M 16.55M 15.11M 28.52M 1.96B 28.66M 196M 75.89M 988M 77.12M 75.45M 3.27B
Net income -115M -98.82M -92.76M -84.72M -160M -10.98B -161M -1.1B -425M -5.54B -432M -423M -18.35B -150M -129M -121M -110M -208M -14.29B -209M -1.43B -554M -7.21B -563M -550M -23.88B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
26/08/26 $4.205 +0.12% 1,415,591
25/08/26 $4.200 +2.44% 4,286,015
24/08/26 $4.100 +2.50% 1,753,265
21/08/26 $4.000 -0.74% 1,161,742
20/08/26 $4.030 -4.28% 2,272,712
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.200USD
Average target price
13.33USD
Spread / Average Target
+217.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock